A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

HCA Florida Northwest Hospital Acquires Anovo Surgical System

HCA Florida Northwest Hospital has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including hysterectomies. The Anovo System is the first and only FDA-authorized surgical robot with features including shoulder, elbow, and wrist joints designed to mimic human arms and provide human level dexterity.

“It is essential for surgeons to use the most advanced tools and technologies to ensure we deliver optimal care to our patients, and this system presents several advantages compared to other available robotic technologies,” said Daniel Gomez, MD, FACOG, FACS, a minimally invasive gynecologic surgeon and assistant program director of the OBGYN Residency Program at HCA Florida Northwest Hospital. “By enabling the transvaginal approach to benign gynecological procedures including benign hysterectomies, we can perform minimally invasive surgery that may deliver benefits including less pain after surgery, leading to a faster recovery, and virtually no visible scarring. We are also excited to train the next generation of gynecologic surgeons on this new platform to further advance the surgical care that our current OBGYN residents will provide to their patients in the future.”

The Anovo Surgical System was granted de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal. Multiple instruments can be introduced to the body through a single portal and the unprecedented articulation offers optimal access and working angles.

Anovo Surgical System is designed to enable surgeons to use the transvaginal approach in gynecological procedures, which has been well documented in clinical research as providing benefits including less patient pain and scarring, shorter recovery times and reduced infection rates, compared to other approaches.[i] In addition, the Anovo System requires a much smaller footprint and costs significantly less than conventional robotic systems, making it possible for more hospitals and ambulatory surgery centers to acquire the system and offer more patients the benefits of less invasive robotic surgery.

“We are pleased to have growing support from leading medical facilities in Florida including HCA Florida Northwest Hospital and hope to continue our momentum as we work to build broader commercial adoption of the Anovo System,” said Dvir Cohen, CEO and Co-Founder of Momentis. “We are dedicated to making this innovative technology available to more women and improving their surgical experience as well as that of the surgeons.”

[i] Aarts JWM, Nieboer TE, Johnson N, Tavender E, Garry R, Mol BWJ, Kluivers KB. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015. 2015 Aug 12;2015(8):CD003677. doi: 10.1002/14651858.CD003677.pub5.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy